Integer Holdings stock analysis
Want to see ITGR full AI Analyst Report?
Integer Holdings (ITGR) Stock Price & Analysis
ITGR Stock Chart & Stats
- Day’s Range
- $126.51 - $126.70
- 52-Week Range
- $66.51 - $126.83
- Previous Close
- $126.42
- Volume
- N/A
- Average Volume (3M)
- 820.96K
- Market Cap
- $4.31B
- Enterprise Value
- $5.71B
- Total Cash (Recent Filing)
- $14.13M
- Total Debt (Recent Filing)
- $1.34B
- Price to Earnings (P/E)
- 42.2
- Beta
- 0.42
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 1.6
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized Medical-device CDMO Platform
Integer’s integrated CDMO capabilities span development through production for complex, regulated medical devices. This breadth can deepen OEM relationships, support repeat manufacturing programs, and create switching friction as customers rely on validated processes and specialized technical expertise.
Positive Free Cash Flow Generation
Positive free cash flow demonstrates that Integer’s operations are currently producing funding beyond reported earnings for debt service, investment, and strategic needs. Although conversion is mixed, continued cash generation provides a durable financial resource as the company manages programs and ownership transition.
Moderate Balance-sheet Leverage
Leverage near 0.79 times equity and a growing equity base indicate a comparatively manageable capital structure. This gives Integer more flexibility than a heavily levered business to absorb operating variability, support customer programs, and pursue longer-term investment without relying entirely on new financing.
Bears Say
Sharp TTM Revenue Decline
The sharp TTM revenue decline interrupts Integer’s previously steady multi-year expansion and weakens the near-term growth profile. Sustained lower revenue could reduce manufacturing utilization, constrain operating leverage, and make it harder for the company to fund capacity or innovation at prior levels.
Operating Margin Compression
The decline in EBIT margin shows that recent revenue is converting into less operating profit than at the 2024 peak. If this pressure persists, it could limit earnings growth even when sales stabilize, reduce internal investment capacity, and make the business more sensitive to changes in program mix or execution.
Higher Debt And Customer Concentration
Higher debt increases financial obligations while deterioration in Other Markets and greater reliance on Cardio & Vascular raise concentration risk. Together, these factors can reduce resilience if the dominant segment weakens, because fewer operating areas would be available to offset pressure.
Integer Holdings News
ITGR FAQ
What was Integer Holdings’s price range in the past 12 months?
What is Integer Holdings’s market cap?
When is Integer Holdings’s upcoming earnings report date?
How were Integer Holdings’s earnings last quarter?
Is Integer Holdings overvalued?
Does Integer Holdings pay dividends?
What is Integer Holdings’s EPS estimate?
How many shares outstanding does Integer Holdings have?
What happened to Integer Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Integer Holdings?
What is the TipRanks Smart Score and how is it calculated?
Integer Holdings Stock Smart Score
Company Description
Integer Holdings
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Payman Khales
- Employees
- 11,000
- Website
- www.integer.net
- Address
- 5830 Granite Parkway, Plano, TX, 75024, US
Integer Holdings (ITGR) Earnings & Revenues
ITGR Earnings Call
Earnings Call SentimentNeutral
The call conveyed a mixed picture: a modest top-line improvement in Q1 (reported +0.5%, organic +1.3%) and several strategic positives (share buybacks, lower interest expense, targeted cost actions, pipeline strength and a Board-initiated strategic review) were offset by meaningful near-term profitability pressures (adjusted operating income down 14%, margin contraction of 230 bps), weaker cash flow in Q1, and a downward revision to full-year 2026 revenue and profit guidance. Management characterizes the demand softness—primarily in electrophysiology—as temporary normalization and emphasized actions to protect long-term growth, but the guidance cuts and margin contraction represent notable near-term headwinds.
View all ITGR earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 6 | 0 |
| Technical Analysis | 4 | 6 | 0 |
| Moving Averages | 12 | 0 | 0 |













